Vaxart Inc - Asset Resilience Ratio
Vaxart Inc (VXRT) has an Asset Resilience Ratio of 5.71% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2025)
This chart shows how Vaxart Inc's Asset Resilience Ratio has changed over time. Check VXRT strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Vaxart Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see VXRT company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $10.28 Million | 5.71% |
| Total Liquid Assets | $10.28 Million | 5.71% |
Asset Resilience Insights
- Limited Liquidity: Vaxart Inc maintains only 5.71% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Vaxart Inc Industry Peers by Asset Resilience Ratio
Compare Vaxart Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Vaxart Inc (2004–2025)
The table below shows the annual Asset Resilience Ratio data for Vaxart Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 5.37% | $9.99 Million | $186.08 Million | -10.55pp |
| 2024-12-31 | 15.92% | $26.49 Million | $166.39 Million | +10.52pp |
| 2023-12-31 | 5.40% | $4.96 Million | $91.83 Million | -26.91pp |
| 2022-12-31 | 32.31% | $49.70 Million | $153.85 Million | +22.02pp |
| 2021-12-31 | 10.28% | $22.74 Million | $221.17 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $152.58 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $35.23 Million | -- |
| 2017-12-31 | 52.12% | $20.90 Million | $40.10 Million | +25.57pp |
| 2016-12-31 | 26.55% | $19.30 Million | $72.70 Million | +10.30pp |
| 2015-12-31 | 16.25% | $12.90 Million | $79.40 Million | +4.93pp |
| 2014-12-31 | 11.32% | $12.90 Million | $114.00 Million | +9.19pp |
| 2011-12-31 | 2.12% | $2.08 Million | $97.97 Million | -45.83pp |
| 2010-12-31 | 47.95% | $54.60 Million | $113.87 Million | +2.65pp |
| 2009-12-31 | 45.30% | $59.49 Million | $131.32 Million | +28.73pp |
| 2008-12-31 | 16.57% | $23.90 Million | $144.22 Million | +15.90pp |
| 2007-12-31 | 0.67% | $1.60 Million | $238.57 Million | -11.55pp |
| 2006-12-31 | 12.22% | $32.50 Million | $265.88 Million | +10.65pp |
| 2005-12-31 | 1.57% | $5.17 Million | $329.34 Million | -0.70pp |
| 2004-12-31 | 2.27% | $8.35 Million | $368.17 Million | -- |
About Vaxart Inc
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; COVID-19 Vaccine, which is in Phas… Read more